Compare CLPS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | BCTX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 36.6M |
| IPO Year | 2017 | 2025 |
| Metric | CLPS | BCTX |
|---|---|---|
| Price | $1.02 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 6.5K | ★ 148.4K |
| Earning Date | 03-06-2026 | 06-15-2026 |
| Dividend Yield | ★ 14.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $2.60 |
| 52 Week High | $1.88 | $14.68 |
| Indicator | CLPS | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 64.20 |
| Support Level | $0.82 | $4.10 |
| Resistance Level | $1.12 | $4.51 |
| Average True Range (ATR) | 0.04 | 0.25 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 71.25 | 85.26 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.